News >

Biomarkers Needed to Refine Use of Novel Combos in mRCC

Brandon Scalea
Published: Wednesday, Apr 17, 2019

Neeraj Agarwal, MD
Neeraj Agarwal, MD
The combination of PD-1 inhibitors and VEGF TKIs has emerged as a promising option for the frontline treatment of patients with metastatic renal cell carcinoma (mRCC), but the lack of biomarkers and refined guidelines for patient selection remain as challenges, said Neeraj Agarwal, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication